Physician profile
David C Fu
NPI 1417270307
$4,017.32
in general payments reported to CMS, 2019-2025
29 companies · $753 in 2025
The $753 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $336 · 2021: $614 · 2022: $750 · 2023: $668 · 2024: $667 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,088.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $743.91 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $448.62 | 2019-2025 | Cequa |
| Glaukos Corporation | $437.19 | 2021-2025 | Photrexa Viscous and Photrexa, Ce-Marked Kxla System |
| Tarsus Pharmaceuticals, INC. | $278.32 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $267.69 | 2022-2025 | Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $208.13 | 2019-2021 | |
| Oyster Point Pharma, INC. | $179.15 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $133.49 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $130.33 | 2020-2022 | |
| Harrow Eye, LLC | $118.63 | 2024-2025 | Vevye |
| Alexion Pharmaceuticals, INC. | $115.55 | 2023-2025 | Ultomiris |
| Alcon Vision LLC | $104.27 | 2021-2025 | Rocklatan |
| Johnson & Johnson Surgical Vision, INC. | $97.87 | 2022-2023 | |
| Ucb, INC. | $84.92 | 2023-2024 | Rystiggo |
| Novartis Pharmaceuticals Corporation | $83.47 | 2019-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $77.27 | 2019-2023 | |
| Thea Pharma INC. | $67.33 | 2023-2025 | Iyuzeh |
| Amgen INC. | $64.26 | 2025 | Tepezza |
| Allergan, INC. | $63.60 | 2021-2022 | |
| Merz North America, INC. | $57.73 | 2019-2020 | |
| Akorn Operating Company LLC | $57.06 | 2021 | |
| Dompe US, INC. | $32.82 | 2024 | Oxervate |
| Catalyst Pharmaceuticals, INC. | $32.22 | 2024 | |
| Horizon Therapeutics Plc | $29.74 | 2022 | |
| Astellas Pharma US INC | $27.92 | 2024 | Izervay |
| Argenx US, INC. | $27.70 | 2023 | Vyvgart |
| Celularity INC. | $17.18 | 2021 | |
| Rxsight INC | $16.15 | 2022 | |
| Eyevance Pharmaceuticals LLC | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.